Skuteczne odstawienie nilotynibu po niepowodzeniu terapii imatynibem

Haematologia Pub Date : 2021-01-07 DOI:10.5603/HEM.2020.0019
Joanna Wącław, Tomasz Sacha
{"title":"Skuteczne odstawienie nilotynibu po niepowodzeniu terapii imatynibem","authors":"Joanna Wącław, Tomasz Sacha","doi":"10.5603/HEM.2020.0019","DOIUrl":null,"url":null,"abstract":"Successful treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKI) is nowadays likely to result in near-normal life expectancy. Nowadays, the treatment-free remission (TFR) is becoming more and more often a therapeutic goal for both hematologist and his patient. TKI discontinuation and maintenance of TFR is feasible in circa 40–50% of CML patients who achieved stable deep molecular response (DMR). Here, we present a patient with CML, who was switched to nilotinib due to imatinib therapy failure. After a few years of sustaining DMR nilotinib was discontinued. One year since this decision, the patient has remained in the TFR.","PeriodicalId":12837,"journal":{"name":"Haematologia","volume":"278 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/HEM.2020.0019","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Successful treatment of chronic myelogenous leukemia (CML) with tyrosine kinase inhibitors (TKI) is nowadays likely to result in near-normal life expectancy. Nowadays, the treatment-free remission (TFR) is becoming more and more often a therapeutic goal for both hematologist and his patient. TKI discontinuation and maintenance of TFR is feasible in circa 40–50% of CML patients who achieved stable deep molecular response (DMR). Here, we present a patient with CML, who was switched to nilotinib due to imatinib therapy failure. After a few years of sustaining DMR nilotinib was discontinued. One year since this decision, the patient has remained in the TFR.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用酪氨酸激酶抑制剂(TKI)成功治疗慢性髓性白血病(CML)现在很可能导致接近正常的预期寿命。目前,无治疗缓解(TFR)越来越成为血液学家和患者的治疗目标。约40-50%达到稳定深度分子反应(DMR)的CML患者停用TKI并维持TFR是可行的。在这里,我们报告了一位CML患者,由于伊马替尼治疗失败而改用尼洛替尼。维持DMR几年后,尼罗替尼停止使用。自该决定作出一年后,患者仍在TFR中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Ocena skuteczności i bezpieczeństwa stosowania terapii iksazomib-lenalidomid-deksametazon w leczeniu nawrotowego/opornego szpiczaka plazmocytowego wysokiego ryzyka cytogenetycznego — wyniki badania obserwacyjnego Polskiej Grupy Szpiczakowej Odstawienie nilotynibu u pacjentki z przewlekłą białaczką szpikową i małopłytkowością będącą powikłaniem leczenia imatynibem Skuteczne odstawienie nilotynibu po niepowodzeniu terapii imatynibem Utrata całkowitej odpowiedzi cytogenetycznej po odstawieniu nilotynibu Wczesny nawrót molekularny po odstawieniu terapii nilotynibem
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1